Temporary local skin irritation involving the vulva, vagina, or penis is the most common problem associated with<unk>  use.Local irritationTemporary skin irritation involving the vulva, vagina, or penis caused by either local toxicity or allergy to the formulation is the most common problem associated with<unk>  use... Although vaginal epithelial disruption has been associated with frequent use (twice a day or more) of<unk> s containing N-9, this is usually asymptomatic. In a low risk population, long-term use of N-9 containing methods was not associated with epithelial disruption.22p. 401:N-9<unk> s are inadvisable if STI/HIV exposure is likely in situations that would involve frequent use defined as 2 times or more a day. Frequent use (two times or more a day) of nonoxynol-9 containing<unk>  is inadvisable if STI/HIV exposure is likely, because in this situation there is increased vulvovaginal epithelial disruption and increased risk of HIV acquisition. In 2007, the United States Food and Drug Administration (FDA) mandated that labels for nonoxynol-9 over-the-counter (OTC) contraceptive products carry a new warning saying they do not protect against STDs and HIV/AIDS.
Spermicide
Male contraceptive
Female condom
Extended cycle combined hormonal contraceptive
Phytoprogestogen
Antiprogestogen
Heat-based contraception
Pessary